cridanimod sodium

Drug Overview

Cridanimod Sodium is an investigational immunomodulatory and antitumor agent being studied primarily in gynecological oncology, with its most significant research focus on endometrial cancer that has stopped responding to progestin-based hormonal therapy. It represents a unique approach in cancer care by combining direct antitumor activity with immune system modulation, making it relevant to both targeted therapy and immunotherapy research programs.

The compound belongs to a class of synthetic acridone derivatives. What makes cridanimod particularly interesting scientifically is its ability to restore hormonal sensitivity in progesterone receptor-negative endometrial tumors, potentially re-sensitizing them to progestin therapy that had previously become ineffective. This mechanism of restoring drug sensitivity is a clinically meaningful strategy in a cancer setting where treatment options after progestin failure are limited.

Key Details:

• Generic Name: Cridanimod Sodium
• US Brand Names: None currently approved
• Drug Class: Immunomodulatory Agent / Antitumor Acridone Derivative / Investigational Progestin Sensitizer
• Route of Administration: Intramuscular (IM) injection; some protocols also investigate vaginal administration
• FDA Approval Status: Investigational. Not FDA-approved for routine clinical use. Studied through authorized clinical trials, with European investigational history predating current US trial activity.

What Is It and How Does It Work? (Mechanism of Action)

Cridanimod Sodium operates through several distinct biological mechanisms simultaneously, which together explain both its antitumor activity and its ability to restore progestin sensitivity in resistant endometrial cancer.

Highlighted Feature: Cridanimod Sodium functions as an Immunomodulatory Targeted Therapy Agent, uniquely capable of restoring progesterone receptor expression in hormone-resistant endometrial tumors while simultaneously stimulating innate immune responses against cancer cells.

Interferon Induction: At the molecular level, cridanimod is a potent inducer of endogenous interferon production, particularly interferon-alpha and interferon-beta. It activates pattern recognition pathways within immune cells, triggering the release of type I interferons that have direct antiproliferative effects on tumor cells. Interferons inhibit cancer cell division, upregulate major histocompatibility complex (MHC) expression on tumor cells to improve immune recognition, and activate natural killer (NK) cells and cytotoxic T-lymphocytes against the tumor.

Progesterone Receptor Re-expression: One of cridanimod’s most clinically remarkable mechanisms is its ability to restore progesterone receptor (PR) expression in endometrial tumor cells that have lost PR expression through epigenetic silencing or transcriptional downregulation. Loss of PR expression is the primary reason endometrial cancers develop resistance to progestin therapy. By restoring PR expression, cridanimod re-sensitizes the tumor to progestin treatment, potentially allowing medroxyprogesterone acetate or other progestins to resume therapeutic activity in previously resistant disease.

NF-κB and Inflammatory Pathway Modulation: Cridanimod modulates NF-κB signaling within tumor cells, reducing the pro-survival and pro-inflammatory transcriptional activity that helps cancer cells evade programmed cell death. This contributes to its direct antiproliferative and pro-apoptotic effects independent of its hormonal sensitization mechanism.

Immune Cell Activation: Beyond interferon induction, cridanimod directly enhances the cytotoxic activity of NK cells and macrophages, strengthening the innate immune surveillance system’s ability to identify and eliminate tumor cells. This broad immune activation complements its tumor-cell-directed mechanisms.

FDA Approved Clinical Indications

Cridanimod Sodium has no FDA-approved indications. All uses listed reflect active clinical trial investigation.

Oncological Uses (In Clinical Trials):

• Progestin-Resistant Endometrial Cancer: Primary investigational indication; studied in combination with medroxyprogesterone acetate to restore progestin sensitivity in PR-negative or progestin-refractory disease
• Recurrent Endometrial Cancer: Investigated for patients with disease recurrence after standard first-line therapy
• Gynecological Malignancies: Broader investigational interest in ovarian and cervical cancer given its immunomodulatory profile
• Hormone Receptor-Negative Gynecological Tumors: Explored as a sensitizing agent to restore hormonal therapy responsiveness in receptor-negative disease

Non-Oncological Uses:

• Cridanimod has historical investigational use as an antiviral immunomodulator in European research, though current development focus is entirely on oncological applications.

Dosage and Administration Protocols

Clinical Efficacy and Research Results

CREDO Trial Program: The most significant clinical evidence base for cridanimod comes from the CREDO (Cridanimod Endometrial Cancer) trial program, which evaluated cridanimod sodium combined with medroxyprogesterone acetate in patients with progestin-resistant or PR-negative recurrent endometrial cancer. This trial was notable for specifically targeting a patient population with no established effective hormonal treatment option.

Biological Activity Confirmation: Clinical data from the CREDO program demonstrated that cridanimod successfully induced measurable changes in tumor biology, including evidence of PR re-expression in tumor tissue samples from treated patients, confirming the drug’s ability to execute its primary mechanistic objective in human subjects.

Clinical Response Signals: The trial reported clinical responses including disease stabilization and objective tumor responses in a meaningful proportion of enrolled patients who had previously progressed on progestin therapy alone. These responses in a population expected to have no hormonal treatment sensitivity represent a clinically significant proof-of-concept finding.

Interferon Pathway Activation: Serial immunological assessments during the CREDO trial confirmed systemic interferon pathway activation following cridanimod administration, validating its immunomodulatory mechanism in humans and supporting the rationale for combination with immune-directed therapies in future trial designs.

Ongoing Development: Updated analyses and extended follow-up data from the CREDO program continue to be evaluated. Larger confirmatory trials are considered necessary to establish progression-free and overall survival benefits sufficient for regulatory submission.

Safety Profile and Side Effects

Cridanimod Sodium’s safety profile, as established through its clinical trial program, is generally manageable and consistent with its immunomodulatory mechanism of action.

Black Box Warning: No FDA Black Box Warning exists for Cridanimod Sodium, as it remains an investigational agent not subject to formal FDA labeling requirements.

Common Side Effects (>10%):

• Injection Site Reactions: Pain, redness, induration, and local discomfort at the intramuscular injection site are the most frequently reported effects
• Flu-Like Symptoms: Fever, chills, fatigue, and myalgia consistent with interferon pathway activation are commonly reported following administration
• Fatigue: General tiredness related to immune activation rather than direct organ toxicity
• Mild Gastrointestinal Symptoms: Nausea and abdominal discomfort reported in a proportion of trial participants

Serious Adverse Events (Rare):

• Autoimmune Phenomena: Sustained interferon induction carries theoretical risk of triggering or exacerbating autoimmune conditions in predisposed patients
• Significant Fatigue or Asthenia: In some patients, immune activation-related fatigue may reach severity requiring dose modification or temporary treatment interruption
• Allergic Reactions: As with any injectable agent, hypersensitivity reactions including urticaria or systemic allergic responses are possible though uncommon

Management Strategies:

• Administer antipyretics such as acetaminophen before injection to reduce flu-like symptom burden
• Rotate intramuscular injection sites systematically to minimize local tissue reactions
• Monitor patients for signs of excessive immune activation and adjust dosing per protocol guidance if significant autoimmune features emerge
• Provide supportive care for fatigue including sleep hygiene counseling, activity modification, and nutritional support

Research Areas

Immunotherapy Combination Potential: Cridanimod’s dual capacity to activate interferon pathways and restore tumor antigen presentation through MHC upregulation makes it a scientifically compelling candidate for combination with immune checkpoint inhibitors. Tumors with restored PR expression and increased MHC presentation may be substantially more responsive to PD-1/PD-L1 blockade. Research programs are exploring whether cridanimod can convert immunologically cold endometrial tumors into hot, immune-infiltrated tumors amenable to checkpoint inhibitor therapy.

Epigenetic Sensitization Research: The mechanism by which cridanimod restores PR expression is believed to involve epigenetic pathway modulation, potentially including effects on DNA methylation or histone modification patterns that silence PR gene transcription. Researchers are investigating whether combining cridanimod with hypomethylating agents could further amplify PR re-expression and broaden its application to other hormone receptor-silenced tumor types beyond endometrial cancer.

Broader Gynecological Oncology Applications: Given its immunomodulatory and hormone-sensitizing mechanisms, cridanimod is being evaluated for potential applications in ovarian cancer and other gynecological malignancies where hormonal pathway modulation and immune activation could offer therapeutic benefit.

Patient Management and Practical Recommendations

Pre-Treatment Tests to Be Performed:

• Progesterone Receptor Status: Tumor tissue testing for PR expression to characterize baseline hormonal receptor status and monitor re-expression during treatment
• Baseline Immunological Assessment: Complete blood count and inflammatory marker panel to characterize immune status before interferon-inducing therapy
• Liver Function Tests: Baseline hepatic assessment given immunomodulatory therapy’s potential hepatic effects
• Autoimmune Disease Screening: Assessment for pre-existing autoimmune conditions that may be worsened by sustained interferon induction
• Pregnancy Test: Mandatory for women of childbearing potential given the oncological and immunological nature of the treatment

Precautions During Treatment:

• Patients with pre-existing autoimmune conditions require heightened monitoring throughout treatment
• Concurrent use of immunosuppressive medications may antagonize cridanimod’s intended immune activation and should be reviewed by the treating oncologist
• All injections must be administered by trained healthcare personnel under clinical trial conditions
• Flu-like symptoms following injection are expected and should be differentiated from signs of serious infection or immune complications

Do’s and Don’ts:

DO:

• Disclose all current medications, supplements, and autoimmune history to your care team before starting treatment
• Report fever, unusual fatigue, respiratory changes, or injection site worsening promptly
• Attend all scheduled assessments including tumor imaging, blood tests, and clinical evaluations
• Take physician-approved antipyretics before injections if flu-like symptoms have been significant in prior doses

DON’T:

• Do not self-administer injections outside of the clinical trial setting
• Do not start immunosuppressive medications during treatment without oncologist approval
• Do not miss scheduled injections without notifying your trial physician
• Do not ignore persistent injection site swelling, redness, or signs of infection

Legal Disclaimer

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Cridanimod Sodium is an investigational agent not approved by the FDA for routine clinical use in any indication. It is available exclusively through authorized clinical trials under qualified medical supervision. All treatment decisions must be made by a licensed oncologist or qualified healthcare professional based on thorough individual clinical evaluation. Consult your treating physician before making any decisions related to your diagnosis, treatment options, or clinical trial participation.